Compare AbbVie Inc (ABBV) vs McCormick & Company, Incorporated (MKC) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

MKC trades at $52.96, up 1.3% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $59.67 suggesting 13% upside. The company reported Q2 2026 results that beat expectations, driven by the McCormick de Mexico acquisition and margin expansion, with revenue growth of 16.7% year-over-year. The pending $65 billion merger with Unilever's food business represents a transformative opportunity, though integration risks remain.

The outlook is positive, supported by strong profitability metrics, including a 21.91% net income margin and 25.7% ROE, alongside a reasonable valuation with a P/E of 8.81. Key risks include execution of the Unilever deal, competitive pressures in the consumer segment, and potential macroeconomic headwinds affecting consumer spending.